CTIM-15. EO2401 PEPTIDE IMMUNOTHERAPY + NIVOLUMAB +/- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: TREATMENT STRATEGY OPTIMIZATION IN THE PHASE 1/2 STUDY EOGBM1-18 / ROSALIE (NCT04116658)

Abstract EO2401, composed of peptide sequences from gut bacteria that cross-react with glioblastoma tumor-associated antigens (IL13Rα2, BIRC5/survivin, and FOXM1) plus a helper peptide, was administered to HLA-A2 positive patients with first progression of a glioblastoma requiring ≤ 2 mg dexamethasone/day. Mature data from cohorts-2a/2b (EO2401/nivolumab, n=44) and 3 (EO2401/nivolumab/bevacizumab, n=26) are provided. Ex vivo tetramer-staining on PBMCs demonstrated expansion of CD8 T-cells specific for EO2401 TAAs in 84% of tested patients for cohort-2a/2b and in 92% for cohort-3. Adverse events were limited to those expected for nivolumab and bevacizumab, as well as local site reactions to EO2401 (96% events grade 1-2). Improved outcomes were observed for cohort-3 (median follow-up 33.5 months) versus 2a/2b (median follow-up 25.0 months) including: time of study therapy (4.8 vs 2.3 months), median PFS (4.8 vs 1.9 months), ORR (38% vs 14%) and median OS (12.1 vs 10.8 months). Median OS for patients who underwent second surgery prior to EO2401 start vs no surgery were 18.5 vs 8.5 months for cohort-3 and 11.1 vs 10.2 months for cohort-2a/2b. Multivariable Cox regression analyses revealed that OS for cohort-3, but not cohort 2a/2b was associated with second surgery (HR=0.08, 95%-CI 0.01–0.75, p=0.027), gender (HR=10.2, 95% CI 2.17–48.3, p=0.003) and baseline dexamethasone use (HR=9.35, 95%-CI 2.03–43.1, p=0.004) whereas MGMT methylation status and tumor size was not. For external validation, application of the same model to the CM-143 dataset (1st glioblastoma progression randomized to nivolumab [n=83] vs bevacizumab [n=77]) revealed no associations with OS for bevacizumab while MGMT status (HR=1.95, 95%-CI 1.12–3.17, p=0.007) and baseline corticosteroid use (HR=2.30, 95%-CI 1.42–3.71, p=0.001) associated with OS for nivolumab. Our data indicate that a randomized trial further evaluating EO2401 is warranted and also suggest that surgery prior to triplet therapy, along with baseline dexamethasone use, should be further investigated.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2025-11-01
DOI
https://doi.org/10.1093/neuonc/noaf201.0472
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

CTIM-15. EO2401 PEPTIDE IMMUNOTHERAPY + NIVOLUMAB +/- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: TREATMENT STRATEGY OPTIMIZATION IN THE PHASE 1/2 STUDY EOGBM1-18 / ROSALIE (NCT04116658)

Mirjam Renovanz, Cécile Gouttefangeas, Alice Hervieu, María Vieito et al.
Neuro-Oncology
Glioma Diagnosis and Treatment
article

CTIM-15. EO2401 PEPTIDE IMMUNOTHERAPY + NIVOLUMAB +/- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: TREATMENT STRATEGY OPTIMIZATION IN THE PHASE 1/2 STUDY EOGBM1-18 / ROSALIE (NCT04116658)

Mirjam Renovanz, Cécile Gouttefangeas, Alice Hervieu, María Vieito, Iris Mildenberger, Michael C. Burger, Patrick Yung Wen, Jan Fagerberg, Antje Wick, François Ghiringhelli, Philippe Rinaudo, Laurent Chêne, David A. Reardon, Agostina Stradella, Ulrich Herrlinger, Mehdi Touat, Marta Gil-Martín, Wolfgang Wick, Ghazaleh Tabatabai, Ahmed Idbaïh, Ana Maia, Macarena González
article en

Abstract

Abstract EO2401, composed of peptide sequences from gut bacteria that cross-react with glioblastoma tumor-associated antigens (IL13Rα2, BIRC5/survivin, and FOXM1) plus a helper peptide, was administered to HLA-A2 positive patients with first progression of a glioblastoma requiring ≤ 2 mg dexamethasone/day. Mature data from cohorts-2a/2b (EO2401/nivolumab, n=44) and 3 (EO2401/nivolumab/bevacizumab, n=26) are provided. Ex vivo tetramer-staining on PBMCs demonstrated expansion of CD8 T-cells specific for EO2401 TAAs in 84% of tested patients for cohort-2a/2b and in 92% for cohort-3. Adverse events were limited to those expected for nivolumab and bevacizumab, as well as local site reactions to EO2401 (96% events grade 1-2). Improved outcomes were observed for cohort-3 (median follow-up 33.5 months) versus 2a/2b (median follow-up 25.0 months) including: time of study therapy (4.8 vs 2.3 months), median PFS (4.8 vs 1.9 months), ORR (38% vs 14%) and median OS (12.1 vs 10.8 months). Median OS for patients who underwent second surgery prior to EO2401 start vs no surgery were 18.5 vs 8.5 months for cohort-3 and 11.1 vs 10.2 months for cohort-2a/2b. Multivariable Cox regression analyses revealed that OS for cohort-3, but not cohort 2a/2b was associated with second surgery (HR=0.08, 95%-CI 0.01–0.75, p=0.027), gender (HR=10.2, 95% CI 2.17–48.3, p=0.003) and baseline dexamethasone use (HR=9.35, 95%-CI 2.03–43.1, p=0.004) whereas MGMT methylation status and tumor size was not. For external validation, application of the same model to the CM-143 dataset (1st glioblastoma progression randomized to nivolumab [n=83] vs bevacizumab [n=77]) revealed no associations with OS for bevacizumab while MGMT status (HR=1.95, 95%-CI 1.12–3.17, p=0.007) and baseline corticosteroid use (HR=2.30, 95%-CI 1.42–3.71, p=0.001) associated with OS for nivolumab. Our data indicate that a randomized trial further evaluating EO2401 is warranted and also suggest that surgery prior to triplet therapy, along with baseline dexamethasone use, should be further investigated.

Neuro-OncologyVol. 27(Supplement_5)
Technische Hochschule Mannheim (DE), Goethe University Frankfurt (DE), University of Mannheim (DE), German Cancer Research Center (DE), Heidelberg University (DE), University Hospital Bonn (DE), University Hospital Heidelberg (DE), Sorbonne Université (FR), Centre Georges François Leclerc (FR), Assistance Publique – Hôpitaux de Paris (FR), Enterome (France) (FR), Dana-Farber Cancer Institute (US), Pitié-Salpêtrière Hospital (FR), Vall d'Hebron Hospital Universitari (ES), Hertie Institute for Clinical Brain Research (DE), Duran i Reynals Hospital (ES), University of Tübingen (DE)
Openalex Percentile: Top 51%
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.